Work

Myasthenia gravis: The evolving therapeutic landscape

Year: 2024

Type: article

Abstract: Pharmacological options in the management of generalized myasthenia gravis (gMG) have expanded rapidly in the last 7 years. There are now several complement inhibitors and neonatal Fc receptor antagonists on the market in many countries for patient management, following the successful completion of Phase 3 studies. In open-label extensions, these agents have proven to be effective over the longer term extending several years, with benefits such as reduction of corticosteroid requirements being observed. In the communication below, we will briefly summarize recent pharmacologic advancements in the management of gMG and outline how these agents are currently being used and may be used in the future. • Pharmacological options in the management of generalized myasthenia gravis (gMG) have expanded rapidly since 2017 • These agents have proven to be effective over the short-term and now longer term extending several years. They are generally well tolerated. • This short communication outlines how these agents are currently being used and may be used in the future.

Source: eNeurologicalSci

DOI: 10.1016/j.ensci.2024.100541

Authors: Gil I. Wolfe, Jonathan E. Hanson, Nicholas J. Silvestri

Institution: University at Buffalo, State University of New York

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,810